235 East 42nd Street
About Pfizer, Inc.
At Pfizer Worldwide Research & Development (WRD), Pfizer’s visionary discovery and development division and the largest research-based biomedical and pharmaceutical company in the world, we're not content waiting to witness the evolution of our industry. Instead, we’re driven by science, building on our current successes and capabilities, playing a critical role in developing critical medicines and treatments for patients around the world.
Pfizer’s OWNIT! Culture
Through Pfizer’s shared mission to impact global health, Pfizer has built a unique OWNIT! culture to empower you to play your part in each of Pfizer’s life-changing achievements. So what does OWNIT! mean? It means taking ownership of your career and the contribution you make to the business and the patients and customers impacted by Pfizer’s business. This encouragement for personal progress allows colleagues to treat each other with honesty and respect, to act quickly and decisively, all to deliver results with commitment and care.
Professional Development at Pfizer
Pfizer’s belief that every person matters is also what proves their commitment to you. Whatever your talent or skill, you will be taught how to become an expert in your field through tools like Pfizer’s Mentor Match online tool and creating detailed career “roadmaps” with your manager that take into account your interests and aspirations as well as Pfizer’s business needs. Managers are also encouraged to provide frequent performance feedback instead of relying solely on yearly evaluations. From here, you’ll be inspired to refine – and redefine – your personal and professional goals.
Diversity at Pfizer
Pfizer believes that diversity is just as crucial to building a successful business as it is to building a vibrant culture. Pfizer’s community is one of the greatest building aspects about their culture. And their Diversity and Inclusion team ensures that every colleague experiences a fair and supportive environment. From holding managers and leaders accountable for creating inclusive and equitable workplaces, to helping colleagues appreciate the value of diversity, Pfizer is a place where people from all backgrounds and abilities can build a fulfilling career and reach their full potential.
Finding Your Community and Making a Difference
With more than 95 Colleague Resource Groups (CRGs) located around the world, working at Pfizer means finding a community. Pfizer offers CRGs focused on the following groups: Asians, Blacks, colleagues with disabilities, Latinos, LGBTQ, Veterans and Women. These CRGs offer support, mentoring and networking opportunities to help members enhance their skills and advance their careers. They also help their communities by participating in volunteer and philanthropic activities, from sponsoring student scholarships to health fairs focused on the unique healthcare concerns of diverse populations.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of today. As one of the world’s premier pharmaceuticals companies, Pfizer’s network and influence spans the entire globe. But in every country and continent, Pfizer colleagues are energized by a unique spirit. No matter the role or responsibility, colleagues are empowered by the belief that the work they do has a direct impact on patients.
3979 articles with Pfizer, Inc.
Eight patients treated with SB-525 gene therapy showed dose-dependent increases in FVIII activity, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels
While this type of personalized therapy is revolutionizing cancer treatment and healthcare, it has some formidable limitations.
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
The United Food and Commercial Workers Local 1500 (UFCW Local 1500) filed a class action lawsuit against AbbVie for allegedly using a group of patents to maintain a monopoly on its blockbuster Humira (adalimumab).
Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer - March 19, 2019
Merck KGaA, Darmstadt, Germany and Pfizer Inc. announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib,* a poly polymerase inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer.
The trial, which paired a checkpoint inhibitor and PARP inhibitor, was not likely to hit endpoints. It was the second ovarian cancer trial failure for the two companies in six months.
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
Merck KGaA, Darmstadt, Germany announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib,* a poly polymerase inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 30, 2019.
3/18/2019The American College of Cardiology (ACC) annual meeting was held this weekend in New Orleans. Here’s a look at some of the top stories that came out of the meeting.
AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention
AUGUSTUS is the largest trial in this high-risk patient population requiring both anticoagulant and antiplatelet therapies
The research has broad potential for targeted treatments for neurological diseases like epilepsy or for pain treatment. Their research was published in the journal Science.
Humira generated nearly $20 billion in revenue for the Illinois-based company. Celgene's Revlimid earned about half-as-much in 2018.
3/12/2019The U.S. Food and Drug Administration has been busy approving new treatments for various diseases. Two days into the new week and the regulatory agency has green lit two therapeutics, while other companies are planning to file for potential approval.
U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1
Pfizer Inc. announced the United States Food and Drug Administration has approved TRAZIMERA™, a biosimilar to Herceptin®,1 for the treatment of human epidermal growth factor receptor-2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.2
Pfizer Inc. announced the pricing of a debt offering consisting of five tranches of notes:
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference - March 5, 2019
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Andy Schmeltz, Global President, Oncology, and Chris Boshoff, Chief Development Officer, Oncology, at the Cowen and Company 39th Annual Healthcare Conference on Tuesday, March 12, 2019 at 9:20 a.m. Eastern Daylight Time.
Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer
Pfizer announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for LORVIQUA®, an anaplastic lymphoma kinase tyrosine kinase inhibitor.
Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
Company also provides update on upcoming presentation from a Phase 2 proof-of-concept study and Phase 3 pivotal trial status
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.